Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Gene Therapy Consortium (GTC) for Gene-Based Clinical Trials Conducted within NeuroNEXT

Award Number: OT2NS138339
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: OTHER
PERIOD OF PERFORMANCE START DATE: 08/15/2025
PERIOD OF PERFORMANCE END DATE: 08/14/2026

Group Awards By:

View Award Description

Gene Therapy Consortium (GTC) for Gene-Based Clinical Trials Conducted within NeuroNEXT - Abstract The long-term objective of the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT) initiative is to efficiently translate advances in neuroscience into treatments for adults and children with neurological disorders through partnerships with government, academia, private foundations, and industry. The goal of this proposal is to establish and operate a Gene Therapy Consortium (GTC) that provides expert advice on clinical trials of gene therapies for ultra-rare adult and pediatric disorders conducted within NeuroNEXT. The GTC will consist of members with expertise in gene-based and gene-targeted therapies, ultra-rare and rare diseases, and clinical trial planning and execution, with particular emphasis on first-in-human or first-in-disease trials, small clinical trials, and adaptive trial designs. The GTC will be organized and managed by the NeuroNEXT Clinical Coordination Center (CCC) and will provide advice as requested for gene therapy proposals. The GTC members will support investigators applying to NeuroNEXT in all phases starting at the conception and planning phases and continuing for funded proposals through implementation, analysis and reporting for gene therapy trials within NeuroNEXT. Ultra-rare diseases affect less than or equal to 6,000 people. Many rare diseases, including ultra-rare diseases, have no FDA-approved therapeutic available and have an identified genetic origin. The NINDS supports gene- based therapy research through the Ultra-Rare Gene-based Therapy (URGenT) program. NINDS announced that they will expand the URGenT program to support the conduct of gene-based therapy clinical trials for ultra rare neurological diseases. Gene therapy proposals will be submitted to the NINDS using the URGenT program synopsis form. NeuroNEXT will serve as a clinical trial network for the conduct of early clinical trials of gene therapy for ultra- rare pediatric and adult neurological disorders. NeuroNEXT is currently comprised of 13 clinical sites, a Clinical Coordinating Center (CCC), and a Data Coordinating Center (DCC). A central goal of NeuroNEXT is to facilitate, from initial conception through final analysis, high-quality early-phase clinical trials and biomarker multisite studies with clear go/no-go decisions by providing efficient methodological, organizational, statistical, and logistical support. Aim 1 is to establish a collaborative and accessible Gene Therapy Consortium (GTC) with members with diverse expertise to support investigators in developing and conducting gene-based and gene- targeted therapies trials within NeuroNEXT. Aim 2 is to establish and implement an efficient process for gene therapy proposals to move from concept to design, implementation, analysis and reporting, in collaboration with the NINDS NeuroNEXT program officials and the NeuroNEXT Data Coordination Center (DCC).


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $2,299,690 )
2025	2025	THE GENERAL HOSPITAL CORPORATION	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	002	1	8/13/2025	SUPPLEMENT FOR EXPANSION	$2,134,862
2025	2025	THE GENERAL HOSPITAL CORPORATION	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	2/27/2025	SUPPLEMENT FOR EXPANSION	$164,828
2025	2024	THE GENERAL HOSPITAL CORPORATION	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	1	3/31/2025	NEW	$0
														Subtotal = $2,299,690

Issue Date FY: 2024 ( Subtotal = $296,964 )
2024	2024	THE GENERAL HOSPITAL CORPORATION	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	2/29/2024	NEW	$296,964
														Subtotal = $296,964

Grand Total All Awards = $2,596,654

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Gene Therapy Consortium (GTC) for Gene-Based Clinical Trials Conducted within NeuroNEXT

Award Number: OT2NS138339

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: OTHER

PERIOD OF PERFORMANCE START DATE: 08/15/2025

PERIOD OF PERFORMANCE END DATE: 08/14/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer